City Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public offering of 11,111,111 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the offering to City are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by City. In addition, City has granted the underwriters a 30-day option to purchase up to an additional 1,666,666 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by City.

City’s common stock is expected to begin trading on the Nasdaq Global Market on October 16, 2026, under the ticker symbol “CTY.” The offering is expected to close on October 19, 2026, subject to satisfaction of customary closing conditions.